Reimbursement basics and tips on coding, coverage and payment
Global Market Access Strategy 2026: Navigating the intersection of clinical evidence and economic value is now a universal requirement. Whether you are addressing US Payer coverage requirements or European G-DRG and GHS shortcuts, success depends on early synchronization of your clinical and reimbursement roadmaps. The resources below complement our core global market access strategy, providing actionable frameworks for medical device, biomed and diagnostic companies navigating coding, coverage, and payment pathways.
As leading medical device reimbursement consultants, our insights bridge the gap between early clinical testing and global commercial success. These resources provide a specialized medical device reimbursement strategy framework to help startups align regulatory tracks with payer expectations.
How to Align Clinical Trial Endpoints with Payer Economic Evidence
Avoid sequential data collection and protect your company from commercial insolvency by integrating payer-specific metrics directly into your early clinical study protocols. This strategic guide explains how to convert regulatory data into commercial value by designing validation studies that satisfy both regulatory safety benchmarks and medical device insurance coverage requirements.
Navigating the Biomed Market Access Pathway — Learn specialized risk-mitigation strategies for handling high-risk financial uncertainty and volatile coverage decisions in biomed commercialization.
The Crucial Role of Clarifying Your Decision Maker – A guide to identifying the stakeholders who actually control the budget in the US healthcare system.
An executive guide to commercialization — Discover the core components required for developing a device-specific reimbursement strategy. This guide breaks down actionable frameworks for mapping out coding, coverage, and payment pathways that satisfy healthcare payers during market launch.
Navigating the dual requirements of commercialization — Learn why medical technology innovators benefit from specialized, proactive medical device reimbursement consulting. This guide breaks down how to align early FDA regulatory clearance tracks with long-term insurance payer expectations to prevent unexpected commercial coverage gaps at launch.
5 Tips for International Medical Device Reimbursement — Essential considerations for harmonizing global clinical data to meet diverse regional payer requirements.
Breaking Common Reimbursement Myths – Debunking the most frequent misconceptions that stall MedTech commercialization.
Overcoming Medical Device Commercialization Barriers — Avoiding the common trap of focusing entirely on regulatory approval while neglecting long-term insurance payment sustainability.
Accelerated Evidence Generation in MedTech Reimbursement — Utilizing efficient, phased validation methodologies to streamline clinical data collection and accelerate market access.
Reimbursement DOs and DON’Ts – Essential strategic tips for medical device startups and established firms alike.
Reimbursement by Distributors (PDF) — Evaluating the pros and cons of delegating reimbursement responsibilities to local distribution partners.
Reimbursement pathways vary significantly by country, requiring market-specific expertise and local payer insight.
Mastering the new CMS RAPID Coverage Pathway - A strategic guide for medical device startups looking to align regulatory endpoints and secure immediate payer coverage for their technology.
The 2026 Strategy Guide to RPM and RTM Reimbursement for MedTech Leaders: Navigate changing compliance and optimize your digital health platform's market access by mastering current RPM and RTM reimbursement strategies. This executive guide details how to handle new short-window thresholds, 10-minute care tiers, and remote monitoring billing codes.
Germany Market Access & Strategy
Secure expedited inpatient market access by leveraging the NUBs Hospital Inpatient Gateway. This guide provides strategic insights into navigating the InEK submission mechanism to obtain extra-budgetary funding for innovative MedTech within the German G-DRG system.
Bridge the gap between launch and long-term coverage by utilizing The German Innovation Fund. This analysis breaks down how early-stage MedTech innovators can secure interim clinical trial funding to build the robust economic evidence base required for permanent nationwide reimbursement.
Navigate the complex framework of the German outpatient sector by understanding the rules for Conditional Medical Device Reimbursement. This guide outlines how to secure evidence-based coverage for innovative technologies used within the physician office setting (Ambulanter Sektor) and listed under the uniform assessment standard (Einheitlicher Bewertungsmaßstab - EBM).
France Market Access & Strategy
Bypass restrictive hospital budget caps by leveraging the specialized Liste en Sus Add-on Guide. This strategic brief outlines how to secure separate, dedicated funding for high-cost innovative technologies outside the baseline French GHS diagnostic-related group hospital rates.
Success requires identifying the specific stakeholder who controls the budget. In the US, this often shifts between the clinical department, the hospital Value Analysis Committee (VAC), and the private payer’s medical director, depending on the site of service.
Strategic synchronization means generating clinical evidence that satisfies both the FDA/CE safety requirements and the payer's demand for economic value. Waiting until after regulatory clearance to plan for reimbursement often leads to a "coverage gap."
The NUB (Neue Untersuchungs- und Behandlungsmethoden) process allows hospitals to apply for additional funding for innovative devices not yet covered by the standard G-DRG system, providing a faster route to market for new technologies.
The Liste en Sus is an "add-on" list in France that allows specific, high-cost innovative medical devices to be reimbursed separately from the standard hospital GHS (Groupes Homogènes de Séjours) rates.
Securing coverage and coding is the most critical step of your commercialization timeline. Our team maps global reimbursement pathways directly to your business goals.
